Navigation Links
Pivotal Registration Trial of OPAXIO Maintenance Therapy in First-Line Ovarian Cancer Reaches Enrollment Milestone of 600 patients, Cell Therapeutics and the Gynecologic Oncology Group Discuss Potential for Early Interim Analysis
Date:9/21/2009

SEATTLE, Sept. 21 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) announced today that it will re-focus its resources on the approval of OPAXIO(TM) for its potential superiority indication in maintenance therapy for ovarian cancer. The Gynecologic Oncology Group (GOG) is conducting an ongoing phase III trial that evaluates the use of 12 months of OPAXIO therapy versus an untreated control arm. To date, 600 patients have been enrolled in this trial. CTI has discussed with the GOG, several strategies for conducting an interim analysis which could potentially result in an earlier registration. In addition, given the encouraging results of treatment of advanced esophageal cancer with OPAXIO to be reported at the upcoming International Society of Gastrointestinal Oncology Annual Meeting, CTI plans on meeting with the Food and Drug Administration (FDA) to discuss an additional registration study utilizing OPAXIO as a radiation sensitizer in the treatment of advanced esophageal cancer.

CTI has notified the European Medicines Agency (EMEA) of its decision to withdraw its Marketing Authorization Application (MAA) for a non-inferiority indication in non-small cell lung cancer (NSCLC).

"Given that we have reached a milestone in the ovarian cancer trial enrollment coupled with the reservations the Committee for Medicinal Products for Human Use (CHMP) expressed about the control arm activity in the NSCL cancer study we believe it makes best sense for CTI to focus its efforts with OPAXIO on superiority applications like the first-line ovarian cancer trial as well as the exciting new potential application as a radiation sensitizer," noted Craig W. Philips, President of CTI. "Both of these studies would be landmark trials and first in class for this novel bioengineered taxane. We look forward to continuing to work with the GOG and ultimately the FDA on a registr
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
5. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
6. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
7. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
8. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
9. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
10. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
11. Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... Sept. 15, 2014  Dr. Navneet Sharda M.D . ... recently announced their continued investment in cutting edge cancer treatments ... at the Center and a national reputation as leaders in ... speaking with multiple cancer survivors who have undergone cancer treatment ... both his warm, friendly manner and his belief in the ...
(Date:9/15/2014)... 15, 2014  Inovio Pharmaceuticals, Inc. (NASDAQ: ... stringent listing criteria for the NASDAQ Global Select Market ... exchange from the NYSE MKT. The company will continue ... NASDAQ Global Select Market, a segment of ... standards of any exchange in the world, requiring that ...
(Date:9/15/2014)... 2014  The Female Health Company (NASDAQ-CM: FHCO) today ... Company,s management team as Executive Vice President of Global ... that Michael Pope will retire from his ... September 15, 2014.  Following his retirement, Mr. Pope will ... Prior to joining The Female Health Company ...
Breaking Medicine Technology:Cancer Care Center Emphasizing Innovative Oncology Treatments 2Inovio Pharmaceuticals (INO) Begins Trading on NASDAQ Global Select Market Exchange 2Inovio Pharmaceuticals (INO) Begins Trading on NASDAQ Global Select Market Exchange 3The Female Health Company Appoints Martin Tayler Executive Vice President of Global Operations 2The Female Health Company Appoints Martin Tayler Executive Vice President of Global Operations 3
... May 9, 2011 Optimer Pharmaceuticals, Inc. (NASDAQ: ... abstracts at the 2011 Digestive Disease Week (DDW) conference ... of DIFICID™ (fidaxomicin), an investigational product for the treatment ... (Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO) The first analysis ...
... Australia and BEIJING, May 9, 2011 Saladax Biomedical, ... diagnostic assays to achieve the promise of personalized medicine ... of its Pacific Rim commercialization team to expand its ... Saladax,s Pacific Rim commercialization team include: ...
Cached Medicine Technology:Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID™ Phase 3 Data 2Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID™ Phase 3 Data 3Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID™ Phase 3 Data 4Saladax Biomedical, Inc. Announces Pacific Rim Commercialization Team in Australia and China 2
(Date:9/15/2014)... September 15, 2014 The Best ... World Report consists of seven hospitals using OnBase as ... Hospital and Cleveland Clinic were ranked at the top ... respectively. The rankings cover nearly 5,000 medical centers across ... 17 hospitals that scored highest in at least six ...
(Date:9/15/2014)... 2014 (HealthDay News) -- U.S. heart experts recommend doctors ... when evaluating young people for underlying heart disease that ... Heart Association and the American College of Cardiology said ... and family medical history along with a physical examination ... (existing from birth) risks for sudden cardiac death. ...
(Date:9/15/2014)... estimated 8% of Americans will suffer from post traumatic ... Brought on by an overwhelming or stressful event or ... physiology of the brain. Understanding how threat is processed ... is essential to developing effective interventions. , New ... of Texas at Dallas published online today in ...
(Date:9/15/2014)... (PRWEB) September 15, 2014 This year, ... its founding in 2007. To mark the special occasion, ... for supporting the village and helping it to get ... safe, secure and fun community for seniors. Members of ... community and live in their own homes. They are ...
(Date:9/15/2014)... HealthDay Reporter MONDAY, Sept. 15, 2014 ... responsible for sending thousands of young children to the hospital ... year between 2007 and 2011, about 9,500 U.S. children younger ... family members, medication, according to the U.S. Centers for Disease ... just 1 or 2 years old," said Dr. Daniel Budnitz, ...
Breaking Medicine News(10 mins):Health News:Seven of Top Ten Hospitals in the U.S. Leverage OnBase by Hyland ECM Solution 2Health News:Heart Docs Don't Recommend Routine ECGs for Young Athletes 2Health News:Heart Docs Don't Recommend Routine ECGs for Young Athletes 3Health News:EEG study findings reveal how fear is processed in the brain 2Health News:Avenidas Village Celebrates Anniversary 2Health News:Small Number of Drugs Behind Kids' Accidental Poisonings: CDC 2Health News:Small Number of Drugs Behind Kids' Accidental Poisonings: CDC 3
... Axel Ullrich, Ph.D., is the recipient of the ... his pioneering work in the translation of genomics-based discoveries ... Director of Molecular Biology at the Max Planck Institute ... expert in gene technology and one of the most ...
... of activity helped men, women regardless of family history ... level of aerobic fitness can significantly reduce stroke risk ... study. , The study, expected to be presented Thursday ... New Orleans, showed 30 minutes or more of brisk ...
... connection, experts say , , THURSDAY, Feb. 21 (HealthDay News) ... anywhere else for that matter, may raise your risk ... , "These authors report a potentially important association between ... said Dr. Steven V. Pacia, director of neurology at ...
... similarities, differences in DNA, studies find , , THURSDAY, ... such examination of human genetic diversity yet conducted, an ... to track differences and similarities between people around the ... Science , a team led by Richard Myers, ...
... drugs raises risk of adverse side effects ... take more than one nonsteroidal anti-inflammatory drug (NSAID) may ... suggests. , NSAIDs, which are available in both prescription ... arthritis. , These drugs are widely available, and patients ...
... release is available in Spanish . , ... field of health. However, they are vitally important for patients ... carried out at the Department of Social Anthropology ... lecturer Rafael Briones Gmez, shows that Spanish hospitals are not ...
Cached Medicine News:Health News:Pezcoller Foundation-AACR International Award for Cancer Research recognizes Axel Ullrich 2Health News:Pezcoller Foundation-AACR International Award for Cancer Research recognizes Axel Ullrich 3Health News:Moderate Aerobic Fitness Levels May Cut Stroke Risk 2Health News:Daytime Dozing Might Raise Stroke Risk 2Health News:Global Analysis of Human DNA Tracks Migration, Identity 2Health News:Global Analysis of Human DNA Tracks Migration, Identity 3Health News:Global Analysis of Human DNA Tracks Migration, Identity 4Health News:Taking Multiple Pain Relievers May Cause Complications 2Health News:Patients' relatives are ignored by the health system and suffer emotional stress 2
... SF (slot format) microfiltration units provide a ... acid in solution onto nitrocellulose or Zeta-Probe ... by using interchangeable templates to form the ... Bio-Dot SF apparatus. Each is available as ...
Dot Blotter - 96-Well Dot Blot...
... base with vacuum stage, porous vacuum plate, reservoir ... instructions. The Model 785 vacuum blotter quickly ... agarose gel onto a nylon membrane. Because it ... nucleic acid samples can be separated on a ...
Mini Trans-Blot and PowerPac 300 System, 110-120 V...
Medicine Products: